Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious ...

About Novartis Immunology At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled. With a growing legacy of first-in-class innovation ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Transforming the treatment and healthcare system landscape using early interventions, pioneering treatments, and innovative partnerships to avoid preventable mortality from cardiovascular disease (CVD ...

The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Novartis uses the open-source Drupal content management framework for many key websites, including our flagship global site Novartis.com, main country sites, portals for healthcare professionals, and ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Age-related diseases, including neurodegenerative diseases and cardiovascular and metabolic diseases, account for a substantial and rising portion of the global health burden. DARe scientists are ...